Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284, At LL&M Congress, Featuring Metabolic Response In Aggressive DLBCL Case After Multiple Failed Therapies

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.A novel differentiated synthetic

• AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.
• A novel differentiated synthetic lethal mechanism targeting DNA repair deficiencies via transcription-coupled nucleotide excision repair (TC-NER), enabling activity regardless of TP53 mutation status or surface antigen expression while overcoming BTK inhibitor and proteasome inhibitor resistance and demonstrating preclinical combination synergy with approved antibody therapies.
• LP-284 addresses the post-CAR-T, post-bispecific treatment gap in both monotherapy and combination settings, targeting a $3-4 billion annual market in relapsed/refractory B-cell cancers.
• The LL&M Congress poster titled, A Phase 1 Study of LP-284 in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphomas and Solid Tumors (NCT06132503), generated interest from both biopharma companies and clinical investigators.

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, today announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress, held October 14-17, 2025, in New York City. The presentation featured a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) who experienced rapid disease progression following four prior treatment regimens, including CAR-T cell therapy and bispecific antibody therapy.

The patient achieved complete metabolic response with non-avid lesions after just two 28-day cycles of LP-284, administered intravenously on days 1, 8, and 15 of each cycle. At study entry, the patient presented with extensive multifocal bony lesions following treatment failure with R-CHOP chemotherapy, radiation therapy, a CD19 CAR-T, and a CD3xCD20 bispecific antibody. This clinical outcome validates LP-284's synthetic lethal mechanism and addresses the critical gap for patients who have exhausted advanced targeted and immunotherapies.